This review checks named examples against their developers and public research programmes as of 28 October 2026. It distinguishes what has been built, what it is designed to do and what would need to be demonstrated in a clinical comparison.
A tissue model is not a replacement organ
Bioprinting places cells and supporting materials in a planned three-dimensional arrangement. Researchers need more than an organ-shaped object: cells must survive, receive nutrients and perform the intended function. An accurate-looking shape is therefore a poor measure of readiness for transplantation.
The Wyss Institute describes vascularized living tissues and tissue-on-chip research with channels that allow perfusion. These constructs provide a way to investigate biological behaviour and drug effects. Keeping a laboratory tissue alive is a meaningful engineering result; replacing the function of a human organ inside a patient is a separate test.
That distinction changes how to read a liver-model announcement. A model used to study toxicity may be useful without being suitable for implantation. Claims that it predicts human drug injury better than another method need a defined validation study. The existence of a commercial research platform does not by itself establish fewer clinical failures or a particular amount of money saved.
The 2026 organ-printing programme is a development goal
In January 2026, ARPA-H announced the teams in its PRINT programme. The programme targets functional, human-sized tissues and organs with working vascular structures. Its description presents major technical achievements as goals still to be reached, rather than replacement organs already available to patients.
For example, the Carnegie Mellon-led team aims to prepare a bioprinted liver for first-in-human trials within five years. That is a research target, not a date when routine liver replacement will become available. Other teams have different tasks, including preclinical validation and constructing liver tissue at clinical scale. Their milestones should not be collapsed into one claim that printed organs are already transforming transplant care.
What SmartFuse is designed to measure
A connected implant belongs in a different category. Intelligent Implants describes SmartFuse as a spinal-fusion system combining an implanted cage, an external power and control module, and a cloud service. Its electrodes are intended to stimulate and measure bone growth. The external wearable supplies power and communicates with the implant.
The developer describes a physician portal for monitoring measurements, system status and compliance. It describes the patient app as a wellness product for compliance coaching and tracking. That does not establish that an app selects an effective rehabilitation programme from a patient’s measured healing rate.
The same page states that SmartFuse remains in research and development and is not for sale in any country. It does not provide an identified clinical comparison supporting the earlier version of this article’s claim of 40% faster bone formation. That number has been removed. Development status alone does not prove there have been no human studies; it does mean a benefit needs its own trial evidence before it is presented as established.
A useful sensor still needs a clinical question
Recording a measurement and improving an outcome are separate achievements. For a sensor-enabled implant, useful questions include whether the measurement reliably reflects healing, whether it changes a treatment decision and whether that decision improves a patient-important outcome. A comparative study should identify its patients, follow-up, adverse events and endpoint.
A useful comparison is research on music perception with cochlear implants. That article separates what a device makes possible from the particular listening outcome a study measures; it is not evidence that a bioprinted tissue or bone-healing implant works.
A bone-growth signal, an imaging result, pain, function and revision surgery are different endpoints. An improvement in one cannot silently stand in for all the others. Similarly, a proposed automatic drug-release mechanism should not be described as routine clinical care without identifying the actual device, authorization and human evidence.
Why living products create additional safety questions
The FDA’s regenerative-medicine research overview identifies issues including immune compatibility, sterility, cell migration and the structural integrity of resorbing scaffolds. Living cells introduce questions that do not disappear when the printer has reproduced the intended geometry. Product classification and regulatory requirements also depend on what the particular product contains and is intended to do.
The strongest way to assess a new announcement is to keep four facts together: the named product, its research stage, the outcome actually measured and its current availability. This preserves the significance of a laboratory advance without turning an engineering demonstration or a development plan into a promise of treatment.
